New 52 Week Low Today

Aerovate Therapeutics Inc AVTE:NASDAQ

RT Quote | NASDAQ | USD
Last | 07/23/21 EDT
14.23UNCH (UNCH)
Volume
36,207
52 week range
13.42 - 29.43

...

Loading . . .
  • Open14.23
  • Day High14.25
  • Day Low13.42
  • Prev Close14.23
  • 52 Week High29.43
  • 52 Week High Date06/30/21
  • 52 Week Low13.42
  • 52 Week Low Date07/23/21

Key Stats

  • Market Cap307.08M
  • Shares Out21.58M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open14.23
  • Day High14.25
  • Day Low13.42
  • Prev Close14.23
  • 52 Week High29.43
  • 52 Week High Date06/30/21
  • 52 Week Low13.42
  • 52 Week Low Date07/23/21
  • Market Cap307.08M
  • Shares Out21.58M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-14.54
  • P/E (TTM)-0.98
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-10.308M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Aerovate Therapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The Company's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse...
Mark Iwicki
Chairman
Tim Noyes
Chief Executive Officer
Benjamin Dake Ph.D.
President
George Eldridge
Chief Financial Officer
Address
200 Berkeley Street, Floor 18
Boston, MA
02116
United States